NORTHVALE, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Elite Pharmaceuticals, Inc. announced that Bernard Berk, Chairman and CEO, will present at the New York Society of Security Analysts (NYSSA) 9th Annual Healthcare Industry Conference Wednesday, December 14th at 11:20am EST.
The NYSSA 9th Annual Healthcare Industry Conference will be held at The Harvard Club, 27 West 44th Street in New York City. For additional information about attending this conference, please call 212-541-4530 or on-line at: http://www.nyssa.org
This presentation will be audio webcast live and can be accessed on Elite’s website at http://www.elitepharma.com .
An archived version will be available for 30 days after the live presentation and can be accessed at the same location.
About Elite Pharmaceuticals
Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. The Company’s strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite’s technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has one product currently being sold commercially and a pipeline of seven drug products under development in the therapeutic areas that include pain management, allergy, cardiovascular and infection. The addressable market for Elite’s current pipeline of products exceeds $6 billion. Elite also has a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in the Elite’s filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The companies undertake no obligation to update any forward-looking statements.
Elite Pharmaceuticals, Inc.
CONTACT: For Elite Pharmaceuticals, Inc., Dianne Will, Investor Relations,+1-518-398-6222, dwill@willstar.net, or Investor Relations, Dian Griesel,or John Nesbett, or Antima “Taz” Sadhukhan, all of The Investor RelationsGroup, +1-212-825-3210
